Latest broker research reports with buy, hold and sell recommendations along with share price targets forecast and upside.
Browse thousands of reports and search by company or broker.
Partially helped by robust growth in domestic business, CCLP posted 12.8% growth in revenues in Q1 at Rs 326.12 crs compared to Rs 289.20 crs in the same quarter a year ago., but slightly lower than Rs 331.58 crs reported in Q4. Part of the fall in revenues in Q1 compared to Q4 is attributed to higher off take of small packs of freeze dried coffee in Q4. Despite rise in green coffee prices and rise in freight costs, OPM expanded by 40 bps in Q1 all thanks to improved product mix. Helped by nearly 15%...
comparison, industry ad-volumes were up 49% YoY. We cut our FY23-FY24 EBITDA estimates by ~5% as yields which are at ~4045% discount as compared to pre-COVID levels may take longer to recover. However, ad-volumes in high yield markets have shown signs of improvement (~7-8% shortfall versus pre-COVID benchmark has narrowed a bit) which is encouraging. We believe MBL has fared well in this challenging environment with 1) volume market share of 20% (highest amongst peers) in...
Another quarter of strong recovery in RevPAR After an initial hiccup in Q1FY22 due to second wave of Covid-19, the company has shown strong recovery in both occupancy and ADR in Q2FY22. For domestic operations, the company's occupancy improved by 2,430bps YoY to 56.6%, while ADR was higher by 52% YoY to Rs8,273. This resulted in 2.5x jump in RevPAR to Rs4,679 in Q2FY22 in the domestic operations. Prudent cost management supported operating margin The company's effective cost management initiatives led to EBITDA of Rs723mn in...
We maintain our FY22E/FY23E EPS estimate and Neutral rating, with a TP of INR635 per share, as valuations fairly capture expected strength in earnings growth and risk an EV disruption to its Scooter business....
Q2FY22 Results: Indian Hotels witnessed a sharp rebound in Q2FY22; revenue reached 72% of pre-Covid levels. Indian Hotels' revenues for Q2FY22 were up 184% YoY, 111% QoQ to | 728.4 crore. EBITDA came in at | 72.8 crore and net loss reduced to | 120.6...
About the stock VST Industries (VST) is among the oldest cigarette company in India, involved in manufacturing and marketing of cigarettes and also trading unmanufactured tobacco. Incorporated in 1930, it is an associate undertaking of...
Robust biosimilar portfolio with partners like Viatris, Sandoz (for future launches), Adagio among others. Biosimilar US pipeline: (Approvals Pegfilgrastim, Trastuzumab, Glargine, Adalimumab); filed - Aspart and Bevacizumab. Global footprint in +120 countries for biosimilars In generics, it is among the world's...
